Vabysmo 6 MG/0.05 ML vial 0.05ML
Ended Awarded
- Contract number
- SPE2DB26FQAAV
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,917
Award facts
- Contract value 100% obligated
- $2,916.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a firm fixed-price delivery order valued at $2,916.80 to DMS Pharmaceutical Group Inc. for the supply of VABYSMO 6 mg/0.05 mL vials. VABYSMO is a prescription pharmaceutical product used in ophthalmology, and this delivery order represents a single transaction under DMS Pharmaceutical Group's broader pharmaceutical supply agreement with DLA. The award was made on November 7, 2025, with an ultimate completion date of December 2, 2025. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, and the place of performance for this delivery order is also in Park Ridge. No set-aside designation was applied to this award, indicating competition was conducted among all eligible vendors.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical consumable support to Department of Defense military healthcare facilities worldwide. The underlying IDC, valued at $499,999,999, was awarded on November 13, 2025, and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month periods. DMS Pharmaceutical Group's performance on this and numerous other delivery orders demonstrates its capability to serve as a critical pharmaceutical supplier for DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FQAAV?
SPE2DB26FQAAV was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DB26FQAAV worth?
The government has obligated $2,917 on SPE2DB26FQAAV.
Is contract SPE2DB26FQAAV an order under another contract?
Yes. SPE2DB26FQAAV is a delivery order under SPE2DB25D9305, an indefinite delivery contract.
Was contract SPE2DB26FQAAV competed?
The extent of competition for SPE2DB26FQAAV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award